ArticlePDF Available

The effect of mastic gum on Helicobacter pylori: A randomized pilot study

Authors:

Abstract

Our aim was to study the effect of pure mastic gum on Helicobacter pylori (H. pylori) eradication in patients suffering from an H. pylori infection Fifty two patients were randomized to receive either 350mg three times a day (tid) of pure mastic gum for 14 days (Group A), or 1,05g tid of pure mastic gum (Group B) for 14 days, or pantoprazole 20mg twice a day (bd) plus pure mastic gum 350mg tid for 14 days (Group C) or pantoprazole 20mg bd plus amoxicillin 1g bd plus clarithromycin 500mg bd for 10 days (Group D). All patients harboured H. pylori before entering the study and that was confirmed by a (13)C urea breath test (UBT). H. pylori eradication was tested by a UBT 5 weeks after completion of the eradication regime. Eradication of H. pylori was confirmed in 4/13 patients in Group A and in 5/13 in Grour B. No patient in Group C achieved eradication whereas 10/13 patients in Group D had a negative UBT. There were no statistically significant differences in mean UBT values in Groups A, B, C although there was a trend in Group A (p=0.08) and in Group B (p=0.064). The difference was significant in Group D (p=0.01). All patients tolerated mastic gum well and no serious adverse events were reported. Mastic gum has bactericidal activity on H. pylori in vivo.
Short Communication
The effect of mastic gum on Helicobacter pylori: A randomized pilot study
K.J. Dabos
, E. Sfika, L.J. Vlatta, G. Giannikopoulos
Department of Gastroenterology, Chios General Hospital Skylitsion, Helenas Venizalou 2, 82100 Chios, Greece
article info
Keywords:
Herbal remedies
Monotherapy
Chios mastiha
abstract
Our aim was to study the effect of pure mastic gum on Helicobacter pylori (H. pylori) eradication in
patients suffering from an H. pylori infection
Fifty two patients were randomized to receive either 350 mg three times a day (tid) of pure mastic
gum for 14 days (Group A), or 1,05 g tid of pure mastic gum (Group B) for 14 days, or pantoprazole 20 mg
twice a day (bd) plus pure mastic gum 350 mg tid for 14 days (Group C) or pantoprazole 20 mg bd plus
amoxicillin 1 g bd plus clarithromycin 500 mg bd for 10 days (Group D). All patients harboured H. pylori
before entering the study and that was confirmed by a
13
C urea breath test (UBT). H. pylori eradication
was tested by a UBT 5 weeks after completion of the eradication regime.
Eradication of H. pylori was confirmed in 4/13 patients in Group A and in 5/13 in Grour B. No patient
in Group C achieved eradication whereas 10/13 patients in Group D had a negative UBT. There were no
statistically significant differences in mean UBT values in Groups A, B, C although there was a trend in
Group A (p= 0.08) and in Group B (p =0.064). The difference was significant in Group D (p= 0.01). All
patients tolerated mastic gum well and no serious adverse events were reported. Mastic gum has
bactericidal activity on H. pylori in vivo.
&2009 Elsevier GmbH. All rights reserved.
Introduction
Helicobacter pylori (H. pylori) is a Gram-negative spiral
bacterium that colonises the stomach. Its prevalence in Europe
is in the range of 10-25% and has been falling during the last
decades while in the developing world it is estimated that its
prevalence is much higher (Magalhaes-Queiroz and Luzza 2006).
Infection with H. pylori is etiologically linked to gastritis, peptic
ulcer disease, primary B cell gastric lymphoma and adenocarci-
noma of the stomach (Lai and Sung 2007;Eslick 2006). H. pylori
can be eradicated but this is difficult to achieve and at least two
antibiotics and an acid suppressant are required to achieve
eradication (Malfetrheiner et al. 2007). Side effects for these
regimes are common and a major concern is the development of
antimicrobial resistance. Development and testing of new safe
alternatives to those regimes is therefore warranted.
Mastic gum is a natural resin that is excreted from the trunk
and branches of the mastic bush (Pistacia Lentiscus var. Chia). This
excretion is produced by incising the bark with a sharp
instrument. Mastic gum appears in the incisions in the form of
tears and exudes in droplets onto the soil. While it is flowing, it is
a gummy, clear liquid; it solidifies in irregular shapes after 15-20
days.
Collection is completed in September. Then it is cleaned first by
hand and then with mechanized means. Finally mastic gum is
sorted, classified and graded according to the color and size of the
granule.
The clean mastic gum granules were milled to fine powder
(particle size o200
m
m) by using a Hosokawa Alpine Fine Impact
Mill 100 UP2 (Hosokawa Alpine, Augsburg, Germany). The
encapsulation of powder was performed using the Profill Capsule
Filling System (Torpac Inc, Mumbai, India). Capsule shells
(Capsulegel, V caps, size 0) were made of Hypromellose (Hydro-
xypropyl methylcellulose) and each contained 0.35 (70,002) g of
mastic powder.
There have been references to mastic gum as a medicinal
product since ancient times. It has successfully been used in
gastrointestinal upsets (Kaliora et al. 2007).
Previous studies have shown some effect of mastic gum on the
healing of peptic ulcers in humans (Al-Habbal et al. 1984;Al Said
et al. 1986). Those studies were conducted before the discovery of
H. pylori. A recent case study has shown no effect of mastic gum
on H. pylori (Bebb et al. 2003).
The aim of our randomised controlled trial was to assess the
efficacy of mastic gum monotherapy or in combination with a
proton pump inhibitor on H. pylori eradication and to compare this
efficacy with the standard treatment regime.
Patients and methods
This prospective randomized controlled trial study was con-
ducted at the Gastroenterology Department of Chios General
ARTICLE IN PRESS
Contents lists available at ScienceDirect
journal homepage: www.elsevier.de/phymed
Phytomedicine
0944-7113/$ - see front matter &2009 Elsevier GmbH. All rights reserved.
doi:10.1016/j.phymed.2009.09.010
Corresponding author. Tel.: +302651080738; fax: + 302651080642.
E-mail address: kostasophia@yahoo.com (K.J. Dabos).
Phytomedicine 17 (2010) 296–299
ARTICLE IN PRESS
Hospital Skylitsion. The study was approved by the Local Ethics
Committee and the Greek Medicines Agency.
All eligible patients had an upper gastrointestinal endoscopy
and were found to harbour H. pylori by a rapid urease test (CLO
test, Kimberky Clark, Draper, Utah, USA).They were then asked to
participate in the study and gave their written informed consent.
Patients were excluded if they had a gastric or duodenal ulcer,
were pregnant women or had used in the previous 4 weeks, non
steroidal anti-inflammatory drugs, anticoagulants, steroids, pro-
ton pump inhibitors or antibiotics. Patients who chewed mastic
gum more than once a week were also excluded from the study.
Patients had confirmation of their H. pylori infection by a
13
C
urea breath test (UBT) (INFAI, York, UK). They were then
randomized to receive either a low dose mastic gum monotherapy
350 mg three times a day (tid) for 14 days, a high dose mastic gum
monotherapy 1g tid for 14 days, a dual regime of mastic gum
350 mg tid and pantoprazole 20 mg bd for 14 days, or a standard
triple therapy which consisted of pantoprazole 20 mg bd,
amoxicillin 1 g bd and clarithromycin 500 mg bd for 10 days.
They were asked to keep a log of adverse events. One week into
the study patients received a telephone call, in which their
compliance was assessed and an enquiry on possible adverse
events was made. At the end of the study a physical examination
was performed as well as routine laboratory tests.
Five weeks after the end of treatment, eradication was tested
with a second UBT.
Pure mastic gum was dispensed in capsule form. It contained
no additives or flavourings that could have an effect on its activity.
The randomization was generated using Proc random (SAS
version 6.9). The randomization code was kept at the Central
Pharmacy of Chios General Hopsital Skylitsion. The technician
who performed the UBTs and the operator who analysed the UBTs
were blinded as to which treatment each patient had received.
Data record and statistical analysis
Data were recorded prospectively in case report forms for all
participating patients. All analysis was conducted by intention to
treat. Results are shown as mean and SEM.
Comparisons between UBT values before and after the
intervention were made using the paired t-test. A pvalue of
o0.05 was taken as significant (two-tail test of significance).
Results and discussion
We enrolled fifty two patients from the Endoscopy unit: 13
received low mastic gum monotherapy 350mg tid for 14 days
(Group A), 13 received high mastic gum monotherapy 1g tid for 14
days (Group B), 13 received mastic gum 350 mg tid and
pantoprazole 20 mg bd for 14 days (Group C) and 13 patients
received triple therapy with pantoprazole 20mg bd, amoxicillin
1 g bd and clarithromycin 500 mg bd for 10 days (Group D).
There were no statistically significant differences between
groups with regards to age, sex, previous use of antibiotics or
proton pump inhibitors.
One patient from Group A completed the study but did not
return for his follow up UBT 5 weeks later. Two patients from
Group C completed the study but did not return for their UBT 5
weeks later. One patient in Group D stopped because of side
effects (diarrhoea and abdominal cramps).
Table 1 shows an overview of the results. Four patients in
group A achieved eradication (30,8%), whereas five in Group B
(38,5%) none in Group C and ten patients in Group D (76,92%)
achieved eradication.
UBT was performed a mean of 8 days (4-14 days) before
starting treatment. It was repeated a mean of 39 days (33-61 days)
after completion of the study medication. Fig. 1 shows mean UBT
values before and after treatment. There was a trend towards
significance in Group A (28.8674.4 vs 18.7673.1) (p= 0.08), and
in Group B (27.1175.2 vs 17.6874.8)(p =0.064). Group C showed
no difference (25.5673.8 vs 23.67 74.7) (p =NS) There was a
statistically significant difference in UBT values in Group D
(26.7373.9 vs 7.8572.8) (p o0.01).In nine patients in Group A
and ten patients in Group B the UBT value post treatment
decreased compared with the UBT value before treatment.
Patients who received mastic gum tolerated it well. One
patient in Group A complained of diarrhoea and another in Group
B complained of nausea. Both completed the therapy as per
protocol. Three patients in Group D complained of abdominal
cramping and diarrhoea, one stopped the treatment on day 4.
This study was designed to evaluate the effect of Mastic gum
on H. pylori in vivo. Our results showed that mastic gum has some
effect on H. pylori in vivo. Nine patients in the monotherapy groups
achieved eradication while in ten more patients the UBT value
decreased compared to the pre-treatment reading. UBT values
have been shown to provide rather accurate estimation of the in
vivo H. pylori load (Perri et al. 1998).
We have also shown that the combination of mastic gum and
pantoprazole was ineffective in eradicating H. pylori but it had no
effect on bacterial load either. Our control group with standard
triple therapy achieved an acceptable eradication rate.
The constituents which might contribute to the therapeutic
effects of mastic gum belong to the class of mono- and
sesquiterpenoids (essential oils) (Barra et al. 2007) and triterpe-
noids (e.g. masticadienonic acid) (Assimopoulou and Papageor-
giou 2005). Previous in vitro studies have shown that crude mastic
gum possesses antibacterial properties against H. pylori (Huwez et
al. 1998;Marone et al. 2001). A recent study has shown that the
acid fraction of mastic gum which contains triterpenic acids and
constitutes about 50% of its total weight has bactrericidal activity
against H. pylori (Paraschos et al. 2007). In particular, moronic acid
seems to be a powerful antibiotic not only against H. pylori but
also other bacteria (Hostettmann-Kaldas and Nakanishi 1979).
The activity of mastic gum against H. pylori in vivo was the
subject of studies with conflicting results. Early studies showed
bactericidal activity on H. pylori in vitro and it was hypothesized
that mastic gum killed H. pylori and thus helped ulcer healing
(Huwez et al. 1998;Marone et al. 2001). Unfortunately, two recent
in vivo studies, one in mice and the other in humans showed no
eradication of H. pylori and only a modest antibacterial activity
(Bebb et al. 2003;Loughlin et al. 2003).
Mastic gum is a herbal remedy and all studies that used mastic
gum on patients showed minimal side effects (Al-Habbal et al.
1984;Al Said et al. 1986;Bebb et al. 2003). Also a recent study on
animals showed that long term use of mastic gum was not
Table 1
Patients in Group A received low dose mastic gum monotherapy for 14 days. Group
B patients received high dose mastic gum monotherapy for 14 days. Group C
patients received mastic gum and pantoprazole for 14 days. Group D received
triple therapy with pantoprazole, amoxicillin and clarithromycin for 10 days.
Results are shown as mean7SEM
Eradication UBT pre UBT post p
Group A 4/13 (30.8%) 28.8674.4 18,76 73.1 0.08
Group B 5/13(38.5%) 27.11 75.2 17.6874.8 0.064
Group C 0/13 25.56 73.8 23.6774.7 NS
Group D 10/13 (76,92%) 26.7373.9 7.8572.8 0.01
Abbreviations: UBT= Urea breath test values.
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299 297
ARTICLE IN PRESS
associated with serious side effects (Kang et al. 2007). As a
considerable fraction of patients harbouring the bacterium are
unable to tolerate triple therapy due to side effects mastic gum
might provide a reasonable alternative in the future.
The fact that the combination of mastic gum and pantoprazole
showed no effect on H. pylori is somewhat surprising. Most active
substances of mastic gum belong to its acidic fraction. They
possibly require an acidic environment in the stomach to
successfully kill H. pylori. Proton pump inhibitors block the
hydrogen potassium ATP enzyme system on the gastric parietal
cells. In that way, they increase the intragastric pH. Buffering the
acidity of the stomach by the proton pump inhibitors could result
in a hostile environment for mastic gum. This hypothesis needs to
be tested in further studies.
We have used two doses of mastic gum in our study the main
reason being that a low dose mastic gum monotherapy has shown
some activity in a previous study (Al-Habbal et al. 1984) while a
high dose monotherapy has been shown to be ineffective in
another study (Bebb et al. 2003).
Our study has limitations, the main one being its small size. We
also did not use two different methods of confirming H. pylori status
after treatment as a second endoscopy was deemed inappropriate.
In conclusion, this proof of principle study showed that mastic
gum possesses antibacterial activity against H. pylori in vivo and is
able to eradicate it from patients. Although even the high dose
monotherapy did not achieve acceptable eradication rates it could
be used as an alternative regime in patients unwilling to undergo
eradication with the triple therapy regime.
Acknowledgements
The study was funded by the Chios Mastic Gum Growers
Association
Konstantinos John Dabos declares that he received a travel
bursary from the sponsor during the study period.
Ekaterini Sfika was an employee of the sponsor during the
study period
Lisa Jo Vlatta and Georgios Giannikopoulos have nothing to declare
The study is registered with Controlled Trials and its registra-
tion number is ISRCTN01756929 The URL of the trial register is
www.controlled-trials.com
References
Al-Habbal, M.J., Al-Habbal, Z., Huwez, F.U., 1984. A double blind controlled clinical
trial of mastic and placebo in the treatment of duodenal ulcer. Clin. Exp.
Pharmacol. Physiol. 11, 541–544.
Al Said, M., Ageel, A.M., Parmar, M.S., Tariq, M., 1986. Evaluation of mastic a crude
drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer
activity. J. Ethnopharmacol. 15, 271–278.
Assimopoulou, A.N., Papageorgiou, V.P., 2005. GC-MS analysis of penta- and
tetracyclic-triterpenes from resin of Pistacia species. Part II. Pistacia terebiuthus
var. Chia. Biomed. Chromatogr. 19 (8), 586–605.
Barra, A., Coroneo, V., Dessi, S., Cabros, P., Angioni, A., 2007. Characterization of the
volatile constituents in the essential oil of Pistacia lentiscus L. from different
origins and its antifungal and antioxidant activity. J. Agric. Food Chem. 55 (17),
7093–7098.
Bebb, J.R., Bailey-Flitter, N., Ala’Aldeen, D., Atherton, J.C., 2003. Mastic gum has
no effect on Helicobacter pylori load in vivo. J. Antimicrob. Chemother. 52,
522–523.
Eslick, J.D., 2006. Helicobacter pylori infection causes gastric cancer? A review of
the epidemiological, meta-analytic and experimental evidence. World J.
Gastroenterol. 12, 2991–2999.
Hostettmann-Kaldas, M., Nakanishi, M., 1979. Moronic acid a simple triterpenoid
keto- acid with antimicrobial activity isolated from Ozorooa mucronata. Planta
Med. 37, 358–360.
Huwez, F.U., Thorwell, D., Cockayne, A., Ala’Aldeen, D.A., 1998. Mastic gum kills
helicobacter pylori. N. Engl. J. Med. 346, 1946.
Kaliora, A.C., Stathopoulou, M.G., Triantafillidis, J.K., Dedoussis, G.V., Andikopoulos,
N.K., 2007. Chios mastic treatment of patients with active Crohn’s disease.
World J. Gastroenterol. 13, 748–753.
Kang, J.S., Wanibuchi, H., Salim, E.I., Kinoshita, A., Fukushima, S., 2007. Evaluation
of the toxicity of mastic gum with 13 weeks dietary administration to F344
rats. Food Chem. Toxicol. 45, 494–501.
Lai, L.H., Sung, J.J., 2007. Helicobacter pylori and benign upper digestive diseases.
Best Pract. Res. Clin. Gastroenterol. 21, 261–279.
Loughlin, M.F., Ala’Aldeen, D.A., Jenks, P.J., 2003. Monotherapy with mastic gum
does not eradicate Helicobacter pylori infection from mice. J. Antimicrob.
Chemother. 51, 367–371.
UBT test values in the four groups
0
5
10
15
20
25
30
35
Before treatment
After treatment
Group A Group B Group C Group D
Fig. 1. Urea breath test (UBT) was reformed a mean of 8 days (4-14 days) before starting treatment. It was repeated a mean of 39 days (33-61 days) after completion of the
study medication. Mean values of UBT before and after treatment are shown There was a trend towards significance in Group A (28.8674.4 vs 18.7673.1) (p= 0.08), and in
Group B (27.1175.2 vs 17.6874.8) (p =0.064). Group C showed no difference (25.56 73.8 vs 23.6774.7) (p =NS) There was a statistically significant difference in UBT
values in Group D (26.7373.9 vs 7.8572.8) (p o0.01).
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299298
ARTICLE IN PRESS
Magalhaes-Queiroz, D.M., Luzza, F., 2006. Epidemiology of Helicobacter pylori
infection. Helicobacter 11 (Suppl.1), 1–5.
Malfetrheiner, P., Megraud, F., O’Morain, C., Bazzoli, F., El-Omar, E., Graham, D., et
al., 2007. Current concepts in the management of Helicobacter pylori infection:
the Masstricht III consensus report. Gut 56, 772–781.
Marone, P., Bono, L., Leone, F., Bona, S., Carretto, E., Perversi, L., 2001. Bactericidal
activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J. Che-
mother. 13, 611–614.
Paraschos, S., Magiatis, P., Mitakou, S., Petraki, K., Kalliaropoulos, A., Maragkou-
dakis, P., et al., 2007. In vitro and in vivo activities of Chios mastic gum extracts
and constituents against Helicobacter pylori. Antimicrob. Agents Chemother. 51,
551–559.
Perri, F., Clemente, R., Pastore, M., Quitadamo, M., Festa, V., Bisceglie, M., et al.,
1998. The C
13
urea breath test as a predictor of intragastric bacterial load
and severity of Helicobacter pylori gastritis. Scand J. Clin. Lab. Invest. 58,
19–27.
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299 299
... A randomized double-blind, placebo-controlled study revealed that β-caryophyllene relieved Helicobacter-infected patients' nausea and epigastric pain and decreased the serum IL-1β levels [177]. Additionally, berberine [178], mastic gum [179], Japanese apricot (Prunus mume Siebold et Zucc.) [180], Korean red ginseng [181], and Brazilian green propolis [182] have demonstrated positive effects on Helicobacter eradication in clinical randomized controlled trials. ...
Article
Full-text available
Background Helicobacter infection, which is the leading cause of gastritis and stomach cancer, has become common worldwide. Almost all Helicobacter-infected patients have chronic active gastritis, also known as Helicobacter-associated gastritis (HAG). However, the eradication rate of Helicobacter is decreasing due to the poor efficacy of current medications, which causes infection to recur, inflammation to persist, and stomach cancer to develop. Natural components have robust antibacterial activity and anti-inflammatory capacity, as confirmed by many studies of alternative natural medicines. Purpose This article aimed to conduct a comprehensive search and meta-analysis to evaluate the efficacy of anti-Helicobacter and anti-inflammatory activities of plant-derived extracts or compounds that can treat HAG in animal experiments. We intended to provide detailed preclinical-research foundation including plant and compound information, as well as the mechanisms by which these plant-derived substances inhibit the progression of Helicobacter infection, gastritis and neoplasms for future study. Methods The systematic review is aligned with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and the protocol was registered in PROSPERO (CRD42024527889). An extensive search was performed across multiple databases, including PubMed, Scopus, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal database (VIP), the Wanfang database, and the China biomedical literature service system (SinoMed), up until November 2023. Meta-analysis on Review Manager software (RevMan 5.4) estimating anti-Helicobacter and anti-inflammatory activity was performed. We used the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk of bias tool to evaluate the risk of bias of each study included. Results Our study encompassed 61 researches, comprised 36 extracts and 37 compounds improving HAG by inhibiting Helicobacter infection, the inflammatory response, oxidative stress, and regulating apoptosis and proliferation. Sixteen families especially Asteraceae, Fabaceae and Rosaceae and nine classes including Terpenoids, Alkaloids, Phenols, and Flavonoids may be promising directions for valuable new drugs. The Meta-analyse demonstrated the plant-base substance treatments possess significant anti-Helicobacter and anti-inflammation activity comparing to control groups. The included plants and compounds confirmed that signaling pathways NF-κB, JAK2/STAT3, MAPK, TLR4/MyD88, PI3K/AKT, NLRP3/Caspase-1 and NRF2/HO-1 play a key role in the progression of HAG. Conclusion Plant-derived extracts or compounds actively improve HAG by modulating relevant mechanisms and signaling pathways, particularly through the anti-Helicobacter and inflammatory regulation ways. Further researches to apply these treatments in humans are needed, which will provide direction for the future development of therapeutic drugs to increase eradication rate and alleviate gastritis.
... Schinus terebinthifolius Raddi is already widely used in clinical practice for conditions such as gingivitis, gastritis, vulvitis, and vaginitis because of its non-steroidal anti-inflammatory activity due to two of its components: schinol, and masticadienoic acid. In addition, other components such as biflavonoids have an anti-inflammatory effect, and turpentine, hydroxymicadienoic acid, terebinthifolic acid, and ursolic acid have antimicrobial activity [16][17][18] . ...
Article
Full-text available
Purpose: To evaluate intravenous meropenem and intraperitoneal 10% aqueous extract of Schinus terebinthifolius (aroeira) in elderly rats after autogenous fecal peritonitis. Methods: Thirty 18-month-old Wistar rats underwent peritonitis with 4 mL/kg of autogenous fecal solution. They were stratified into groups: control without treatment; study I, treated with meropenem (40 mg/kg); and study II, treated with meropenem at the same dose and intraperitoneal 10% aqueous extract of aroeira. The animals were monitored for 15 days until euthanasia. The study was approved by Ethics Committee. Results: There was no significant weight loss in the study-II group (p = 0.6277), while the study-I group showed partially recovered weight (p = 0.0187). The study-II group had 90% negative blood cultures, while the study-I group had in 50% of the animals (p = 0.1479). Survival in the study-II group was higher than in study-I group (p = 0.0462). The morbidity score for abdominal and thoracic cavity was lower in the study-II group as compared with study-I group (p = 0.0001). Conclusions: The use of meropenem associated with the intraperitoneal 10% aqueous aroeira extract after induction of autogenous fecal peritonitis in elderly rats produced greater survival, less weight loss, and lower morbidity compared to the use of meropenem alone. Key words Peritonitis; Aged; Carbapenems; Rats; Anacardiaceae
... Previous studies have examined mastiha's antibacterial [13,14], antioxidant [15][16][17], anti-inflammatory [18,19], and cytotoxic properties [20], as well as its hypolipidaemic effect [21] and its impact on liver and intestine wellbeing [22,23]. The results of the previously mentioned studies are promising and, in future, Mastiha might be a significant dietary supplement [24]. ...
Article
Full-text available
In the present study, the processing, characterization, and assessment of novel non-alcoholic and sugar-free drinks based on bioactive extracts from valuable natural sources, such as green tea enriched with Chios mastiha, are considered. Currently, the transition towards the consumption of healthy and sustainable food and beverages promoting human health and well-being is strongly encouraged and biologically active compounds from natural resources have a broad range of ap-plications in this sector. In this context, three beverages (all non-alcoholic, non-carbonated, and sugar-free) were created, including extracts of green tea with Chios mastiha, matcha green tea with Chios mastiha and louisa green tea with Chios mastiha, and an evaluation of their biological potential was performed. Specifically, an analysis of water, extracts, and additives for the beverage production was carried out. Microbiological and nutritional value determination was also conducted in samples of the three products. According to the experimental results, the novel health beverage produced from green tea enriched with Chios Mastiha extracts was found to have improved organoleptic characteristics and was microbiologically stable and safe for a period of 180 days from the production date at 25 °C. It is also considered stable and safe for 3 days after production, even if it remains open at 25 °C. In view of a possible scale-up of this application, safety, and preservation control should continue for at least 540 days from the date of production. In conclusion, the current research findings support the development of a novel non-alcoholic sugar-free health drink based on bioactive extracts from green tea enriched with Chios mastiha, to contribute to maintaining human health and also to strengthen the economy.
... Oral mastic has anti-Helicobacter pylori (H. pylori) effect [24][25][26] as well as digestive aid [16] and antioxidant [27] properties and has been studied as a complementary treatment in the Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) [28]. In a previous study, the effect of applying 350 mg/BD of Pistacia atlantica resin for 4 weeks was compared with placebo and a significant decrease was observed in the severity and frequency of early satiation, pain, and nausea in the Pistacia atlantica-treated group compared to the placebo group [4]. ...
Article
Full-text available
Background: The main goal of the present study was to evaluate the effect of topical mastic oil, compared to placebo on treatment of functional dyspepsia (FD). Materials and Methods: Sixty-three patients with FD were included. Thirty-two subjects received the topical mastic oil (10 drops/TDS after meal) with massage and 31 patients received topical sesame oil with massage. Both groups received pantoprazole (40 mg daily) along with oil and massage. The severity of early satiation, postprandial fullness, epigastric pain and epigastric burning was assessed after 4 weeks using the Visual Analogue Scale (VAS) as well as frequency of symptoms. Satisfaction with the treatment was also assessed using a researcher-made questionnaire. Changes in the severity of symptoms were evaluated by Friedman’s test. Results: Mean and standard deviation of age of the subjects were equal to 36.95±13.64 and 50 (79.4%) patients were female. Both groups experienced a significant decrease in the severity of all the four symptoms (P<0.001). The percentage of decrease in the severity of early satiation was significantly higher in the mastic group than the control group (76.03±34.91% vs. 37.24±38.86%, P=0.003). No significant differences were found in the percentage of decrease in the severity of postprandial fullness, epigastric pain and burning between the study groups (P=0.05, 0.06, and 0.13, respectively). The frequency of symptoms was decreased similarly in both groups. Satisfaction with the treatment was reported to be significantly higher in the mastic group than the sesame group (P=0.01). There were no intolerable side effects in both groups. Conclusion: Mastic oil reduced early satiation better than the placebo. In addition, satisfaction with the treatment was higher in the mastic group than the sesame group. [GMJ.2021;10:e1965]
Chapter
Metabolites of Medicinal Plants: Insightful Approaches provides a comprehensive exploration of the bioactive compounds found in medicinal plants and their pharmacological significance. The book covers key topics such as the economics of medicinal and anticancer plants, phytochemistry, therapeutic potential, and advanced applications like nanotechnology-based drug delivery systems and CRISPR-Cas techniques. It also examines the role of these plants in combating diseases like diabetes and metabolic syndrome and their role in traditional medicine systems. This resource is essential for students, researchers, and professionals in phytochemistry, pharmacology, drug discovery, and healthcare practices. Key Features: 1. Wide range of topics from medicinal plant economics to pharmacological applications. 2. Latest discoveries in plant bioactive compounds and their therapeutic uses. 3. Novel drug delivery methods to enhance efficacy. 4. Linking genes to metabolites through advanced omics approaches.
Preprint
Full-text available
Background: Helicobacter pylori (H. pylori) infection remains a persistent health problem in Korea, where the prevalence of peptic ulcers and gastric cancer is high. This study aimed to determine whether phospholipid-based lipid nanoparticles containing curcumin and mastic gum are beneficial in the treatment of H. pylori infection. Materials and Methods: This was a prospective single-arm pilot study. Patients with confirmed H. pylori infection (delta >8.5) according to a ¹³C-urea breath test (UBT) were included in this study. The study's primary endpoint was to determine the change in the delta UBT values after consuming curcumin-mastic concentrate powder three times a day for 10 days. The rates of H. pylori eradication with standard H. pylori eradication regimens, clarithromycin-based triple therapy, and bismuth quadruple therapy were evaluated. Results: A total of 25 patients participated in the study, with a mean age of 64.44±10.03 years, including 16 male (64.0%) and nine female (36.0%). After 10 days of consuming curcumin-mastic concentrate, the mean delta value of the UBT significantly decreased from 31.85±21.54 to 21.36±21.47 (mean difference=-10.49, P=0.018). Six (24.0%) patients achieved H. pylori eradication after ingesting a curcumin-mastic concentrate (delta value <2.5). The H. pylori eradication rate increased to 56.5% after clarithromycin-based triple therapy and to 85.0% after additional bismuth quadruple therapy. No adverse events related to curcumin-mastic concentrate intake were reported during the study period. Conclusions: Curcumin-mastic concentrate has been demonstrated to reduce H. pylori activity safely in humans. This study suggests that administering curcumin-mastic concentrate before H. pylori eradication treatment may improve eradication rates; however, further large randomized controlled trials are needed to confirm this finding.
Article
Full-text available
The rising risks of food microbial contamination and foodborne pathogens resistance have prompted an increasing interest in natural antimicrobials as promising alternatives to synthetic antimicrobials. Essential oils (EOs) obtained from natural sources have shown promising anticancer, antimicrobial, and antioxidant activities. EOs extracted from the resins of Pistacia lentiscus var. Chia are widely utilized for the treatment of skin inflammations, gastrointestinal disorders, respiratory infections, wound healing, and cancers. The therapeutic benefits of P. lentiscusessential oils (PO) are limited by their low solubility, poor bioavailability, and high volatility. Nanoencapsulation of PO can improve their physicochemical properties and consequently their therapeutic efficacy while overcoming their undesirable side effects. Hence, PO was extracted from the resins of P. lentiscusvia hydrodistillation. Then, PO was encapsulated into (2-hydroxypropyl)-beta-cyclodextrin (HPβCD) via freeze-drying. The obtained inclusion complexes (PO-ICs) appeared as round vesicles (22.62 to 63.19 nm) forming several agglomerations (180 to 350 nm), as detected by UHR-TEM, with remarkable entrapment efficiency (89.59 ± 1.47%) and a PDI of 0.1475 ± 0.0005. Furthermore, the encapsulation and stability of PO-ICs were confirmed via FE-SEM, 1 H NMR, 2D HNMR (NOESY), FT-IR, UHR-TEM, and DSC. DSC revealed a higher thermal stability of the PO-ICs, reaching 351.0°C. PO-ICs exerted substantial antibacterial activity against Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli as compared to free PO. PO-ICs showed significant enhancement in the antibacterial activity of the encapsulated PO against S. aureus with an MIC90 of 2.84 mg/mL and against P. aeruginosa with MIC90 of 3.62 mg/ mL and MIC50 of 0.56 mg/mL. In addition, PO-ICs showed greater antimicrobial activity against E. coli by 6-fold with an MIC90 of 0.89 mg/mL, compared to free PO, which showed an MIC90 of 5.38 mg/mL. In conclusion, the encapsulation of PO into HPβCD enhanced its aqueous solubility, stability, and penetration ability, resulting in a significantly higher antibacterial activity.
Article
Full-text available
To the Editor: Even low doses of mastic gum — 1 mg per day for two weeks — can cure peptic ulcers very rapidly, but the mechanism responsible has not been clear. We have found that mastic is active against Helicobacter pylori, which could explain its therapeutic effect in patients with peptic ulcers. Mastic is a resinous exudate obtained from the stem and the main leaves of Pistacia lentiscus. It is used as a food ingredient in the Mediterranean region. Clinically, mastic has been effective in the treatment of benign gastric ulcers1 and duodenal ulcers.2 In rats, mastic showed cytoprotective . . .
Article
Full-text available
To determine the ability of mastic monotherapy to eradicate Helicobacter pylori infection from mice. The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain-heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori. The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infected mice. Mastic failed to eradicate infection from any of the 18 SS1-infected mice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen. Despite reported beneficial effects in ulcer patients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pylori infection from mice.
Article
1. A double‐blind clinical trial was carried out on thirty‐eight patients with symptomatic and endoscopically proven duodenal ulcer to compare the therapeutic responses to mastic (1 g daily, twenty patients) and placebo (lactose, 1 g daily, eighteen patients) given orally over a period of 2 weeks. 2. Symptomatic relief was obtained in sixteen (80%) patients on mastic and in nine (50%) patients on placebo, while endoscopically proven healing occurred in fourteen (70%) patients on mastic and four (22%) patients on placebo. The differences between treatments were highly significant ( P <0.01). Mastic was well tolerated and did not produce side effects. 3. It is concluded that mastic has an ulcer healing effect, but further studies are needed to establish its role in treating peptic ulcer.
Article
Root bark extract of the East African medicinal plant Ozoroa mucronata showed antimicrobial activity against Gram–positive bacteria. Fractionation of the extract following the results of bioassay led to isolation of the active factor C30H46O3. Spectroscopic studies indicated the olean–18–ene keto acid structure 1 („moronic acid”), isolated for the first time in nature. The relatively simple structure of this bioactive triterpene is noted.
Article
The effect of mastic, a concrete resinous exudate obtained from the stem of the tree Pistacia lentiscus, has been studied on experimentally-induced gastric and duodenal ulcers in rats. Mastic at an oral dose of 500 mg/kg produced a significant reduction in the intensity of gastric mucosal damage induced by pyloric ligation, aspirin, phenylbutazone, reserpine and restraint + cold stress. It produced a significant decrease of free acidity in 6-h pylorus-ligated rats and a marked cytoprotective effect against 50% ethanol in rats which could be reversed by prior treatment with indomethacin. The protective effect was not seen when it was given intraperitoneally in phenylbutazone and restraint + cold stress models. The reduction in the intensity of ulceration in cysteamine-induced duodenal ulcers was not found to be statistically significant in mastic-pretreated rats. The results suggest that mild antisecretory and a localized adaptive cytoprotectant action may be responsible for its anti-ulcer activity. These observations support the results of an earlier study on the clinical effectiveness of mastic in the therapy of duodenal ulcer.
Article
The urea breath test (UBT) has been proposed as the most accurate test for diagnosing Helicobacter pylori infection. The aim of this work was to evaluate the accuracy of the UBT and to compare the results with histologic and endoscopic findings in H. pylori infected patients. One-hundred-and-seventy-two consecutive dyspeptic outpatients were studied by means of endoscopy (with histology and culture), UBT (75 mg 13C-urea), and serology. Gastritis was classified in accordance with the Sydney criteria. In H. pylori positive patients, the bacterial load was assessed semiquantitatively, the number of bacteria in histologic specimens being counted. UBT results were expressed either as percentage cumulative dose of 13CO2 excreted at 1 h (CD60) or delta over baseline at 30' (DOB30). Of 172 patients, 126 (73%) were H. pylori positive on histology or culture. Using a cut-off value of 3.3/1000 for DOB30, the sensitivity, specificity and accuracy of the UBT were 96%, 93.5%, and 95.3%, respectively. A significant correlation was observed between DOB30 values and intragastric bacterial load (r = 0.32). Moreover, a significant difference in DOB30 values was found between patients sorted by the depth of inflammation (chi(2) = 4.36, p = 0.036). No correlation was observed between DOB30 and endoscopic findings in H. pylori positive subjects. The UBT is an accurate non-invasive diagnostic tool and can be used to predict both the intragastric bacterial load and the severity of related gastritis.
Article
In this study we evaluated the antibacterial activity of mastic gum, a resin obtained from the Pistacia lentiscus tree, against clinical isolates of Helicobacter pylori. The minimal bactericidal concentrations (MBCs) were obtained by a microdilution assay. Mastic gum killed 50% of the strains tested at a concentration of 125 microg/ml and 90% at a concentration of 500 microg/ml. The influence of sub-MBCs of mastic gum on the morphologies of H. pylori was evaluated by transmission electron microscopy. The lentiscus resin induced blebbing, morphological abnormalities and cellular fragmentation in H. pylori cells.